The Association of American Medical Colleges (AAMC) and the Council on Governmental Relations (COGR) submitted joint comments to the DEA in support of the proposed...
Cannabis/Controlled Substances
Regulatory requirements associated with clinical and non-clinical research on Schedule I and II Controlled Substances (including cannabis) and issues arising from differences between state and federal laws governing cannabis research.
Featured
COGR Submits Response to Congressional RFI on Federal Regulation of CBD Products
COGR submitted comments in response to a federal Request for Information regarding cannabidiol (CBD). COGR’s letter emphasizes the importance of continued research...
COGR Responds to HHS Notice of Proposed Rulemaking “Confidentiality of Substance Abuse Disorder Patient Records”
COGR, representing over 200 U.S. research institutions, submitted comments on the Department of Health and Human Services' proposed rule to align the confidentiality...
Resources
Point of Contact
Kristin West
Director, Research Ethics & Compliance
All Cannabis/Controlled Substances Articles
COGR Submits Letter to DEA Regarding Production Quotas for Schedule I & II Controlled Substances
COGR submitted formal comments to the U.S. Drug Enforcement Administration (DEA) regarding the proposed 2019 aggregate production quotas for Schedule I and II controlled substances, with particular attention to marijuana and its derivatives. COGR expressly supports the proposed increase in production quotas for marijuana and tetrahydrocannabinols, seeing this as a constructive move to advance scie
